Savella is a brand-name medication that contains milnacipran as its active ingredient. It is classified under the neurology therapeutic area and is supplied as 25 mg tablets. In Hong Kong, Savella is a prescription-only product and is regulated by the Hong Kong Department of Health, which follows standards consistent with those of the U.S. FDA and the European EMA. The medication is marketed by Pfizer.
Milnacipran belongs to the serotonin-norepinephrine reuptake inhibitor (SNRI) class, a group of drugs that influence the balance of neurotransmitters in the central nervous system. The tablet formulation is intended for oral administration and is typically taken once daily, unless a prescriber advises otherwise.
Milnacipran inhibits the reuptake of two key neurotransmitters-serotonin and norepinephrine-by blocking their respective transporters (SERT and NET). By preventing these neurotransmitters from being reabsorbed into nerve terminals, milnacipran increases their levels in the synaptic cleft, which enhances pain-modulating pathways in the brain and spinal cord.
This dual action helps alleviate chronic pain signals that are characteristic of conditions such as fibromyalgia. The drug has a rapid onset of action, with therapeutic effects often noticeable within a few weeks of consistent use. Its bioavailability after oral dosing is moderate, and it is metabolized primarily by the liver before being excreted in the urine.
Savella is approved by regulatory agencies for the management of fibromyalgia, a chronic disorder marked by widespread musculoskeletal pain, fatigue, and tenderness. In Hong Kong, the indication aligns with those approved by the FDA and EMA, emphasizing the drug’s role in reducing pain severity and improving functional capacity.
Typical patients are adults who have experienced persistent fibromyalgia symptoms despite non-pharmacologic interventions such as physical therapy and exercise. The medication is not intended for acute pain episodes but rather for long-term symptom control under close medical supervision.
Absolute contraindications
Known hypersensitivity to milnacipran or any tablet excipients
Concurrent use of monoamine oxidase inhibitors (MAOIs) or use within 14 days of stopping an MAOI
Uncontrolled hypertension (systolic ≥ 180 mmHg or diastolic ≥ 110 mmHg)
Severe hepatic impairment (Child-Pugh class C)
Relative contraindications
Moderate renal impairment (creatinine clearance 30-60 mL/min) - dose adjustment may be required
History of cardiovascular disease (e.g., coronary artery disease) - monitor blood pressure closely
Pregnancy and breastfeeding - milnacipran is classified as a pregnancy-category C drug; risks and benefits must be weighed by a healthcare provider
Elderly patients - increased sensitivity to side effects such as dizziness or hyponatremia
Patients with any of the above conditions should discuss alternatives with their prescriber before initiating Savella.
These effects are usually mild to moderate and often improve with continued treatment. If they persist or worsen, patients should inform their prescriber.
Any sudden or severe symptom should prompt immediate medical attention.
Major interactions
MAO inhibitors (e.g., phenelzine, tranylcypromine): co-administration can precipitate hypertensive crisis or serotonin syndrome. A 14-day washout period is required before switching.
Other serotonergic agents (e.g., selective serotonin reuptake inhibitors, tramadol, triptans): increase risk of serotonin syndrome.
Moderate interactions
CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may raise milnacipran plasma levels; dose adjustment may be needed.
Antihypertensive drugs: milnacipran can elevate blood pressure, potentially counteracting antihypertensive therapy.
Patients should provide a complete medication list-including over-the-counter drugs and herbal supplements-to their prescriber.
Patients should attend scheduled follow-up appointments and report any new or worsening symptoms promptly.
This article provides educational information about Savella and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
Milnacipran may be combined with non-opioid analgesics such as acetaminophen, but concurrent use with other serotonergic pain medications (e.g., tramadol) increases the risk of serotonin syndrome. Coordination with a prescriber is essential before adding any new analgesic.
Standard workplace drug screens typically do not detect milnacipran. However, specialized testing could identify the compound if specifically requested.
Mild nausea often improves with continued therapy. If nausea is persistent or severe, contact your prescriber-they may adjust the dose, suggest taking the tablet with food, or prescribe an anti-emetic.
Rarely, patients report blurred vision or light sensitivity. Should visual disturbances occur, seek medical evaluation promptly.
Both drugs increase serotonin and norepinephrine levels, but milnacipran has a higher norepinephrine-to-serotonin reuptake inhibition ratio. Clinical choices depend on individual response, side-effect profiles, and prescriber preference.
Yes, provided you carry the medication in its original labeled container and have a copy of the prescription. Some countries may require additional documentation; verify local regulations before travel.
The tablet is not formulated for crushing. If swallowing is problematic, discuss alternative formulations or a different medication with your healthcare provider.
Some patients experience insomnia, especially when dosing is taken later in the day. Taking the tablet in the morning may mitigate sleep disturbances.
Milnacipran is not known to cause significant changes in glucose metabolism, but patients with diabetes should monitor their blood sugar as part of routine care.
Because Savella can cause dizziness, fatigue, or visual changes, individuals operating aircraft or heavy machinery should ensure they are stable on the medication before performing such duties. Regulatory bodies may require a medical assessment.
